- Conditions
- Schizophrenia
- Interventions
- Plasticity-based Cognitive Training, Non-plasticity-based Training
- Other
- Lead sponsor
- Posit Science Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 2
- States / cities
- Palo Alto, California • San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Amputation of Lower Limb Above Knee, Amputee, Amputation
- Interventions
- Bio Leg
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- First-Episode Psychosis
- Interventions
- Financial Incentive and Text-Messages
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Raleigh, North Carolina • Philadelphia, Pennsylvania • Philadephia, Pennsylvania
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection, COVID-19, COVID-19 Pandemic, COVID-19 Virus Disease, COVID-19 Virus Infection, Covid19, Coronavirus Disease 2019, SARS-CoV2 Infection, SARS-CoV-2 Acute Respiratory Disease
- Interventions
- Famotidine, Celecoxib, Placebo
- Drug
- Lead sponsor
- Leidos Life Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 15
- States / cities
- Newport Beach, California • Miami, Florida • Atlanta, Georgia + 12 more
- Conditions
- Suicide
- Interventions
- Stage 1 Treatment as usual (TAU), Stage 1 CAMS, Stage 2 CAMS, Stage 2 Dialectical Behavioral Therapy (DBT)
- Behavioral
- Lead sponsor
- University of Nevada, Reno
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trastuzumab, AMG 386 and Trastuzumab, T-DM1 and Pertuzumab, Pertuzumab and Trastuzumab, Ganetespib, ABT-888, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, Amcenestrant + Abemaciclib, Amcenestrant + Letrozole, ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, Datopotamab deruxtecan, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel, GSK 5733584, GSK 5733584 + Dostarlimab, Ivonescimab (20mg/kg Q3W)
- Drug
- Lead sponsor
- QuantumLeap Healthcare Collaborative
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2031
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 36 more
- Conditions
- Cancer, Cancer Survivors, Informal Caregivers, Psychological Distress
- Interventions
- Adaptive Symptom Management and Survivorship Handbook (SMSH) and Telephone Interpersonal Counseling (TIP-C), NCI Brochure
- Behavioral
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Autism Spectrum Disorder, Developmental Delay
- Interventions
- Saliva collection, Vineland Adaptive Behavior Scale-II Assessment
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 18 Months to 6 Years
- Enrollment
- 304 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Children at Risk for ASD
- Interventions
- Baby JASPER, Standard Baby Classroom
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 12 Months to 21 Months
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Thermal Burn
- Interventions
- PermeaDerm®, Mepilex Ag
- Device
- Lead sponsor
- Stedical Scientific, Inc.
- Industry
- Eligibility
- Up to 75 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
- Interventions
- Tazemetostat, Placebo oral tablet, Lenalidomide, Rituximab
- Drug · Combination Product
- Lead sponsor
- Epizyme, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 599 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 57
- States / cities
- Mobile, Alabama • Tucson, Arizona • Cerritos, California + 47 more
- Conditions
- Retinitis Pigmentosa
- Interventions
- Ophthalmic examinations, Mobility Test
- Other
- Lead sponsor
- SparingVision
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Prostate Carcinoma
- Interventions
- Health Education, Informational Intervention, Survey Administration
- Behavioral · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Primary Hyperoxaluria Type 1 (PH1)
- Interventions
- ABO-101
- Drug
- Lead sponsor
- Arbor Biotechnologies
- Industry
- Eligibility
- 6 Years to 64 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2043
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Saint Paul, Minnesota
- Conditions
- Delayed Graft Function
- Interventions
- OPN-305, Placebo
- Drug
- Lead sponsor
- Opsona Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Tampa, Florida + 10 more
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- ADCT-402
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 10
- States / cities
- La Jolla, California • New Haven, Connecticut • Atlanta, Georgia + 7 more
- Conditions
- Physical Activity
- Interventions
- HeartSteps
- Behavioral
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Septic Shock
- Interventions
- selepressin, placebo
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 868 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 17
- States / cities
- Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more
- Conditions
- Respiratory Tract Infection
- Interventions
- Respiratory Inductive Plethysmography
- Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 0 Days to 3 Years
- Enrollment
- 267 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
- Interventions
- Moderate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE)
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Hip Exoskeleton-Assisted Walking
- Device
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 45 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Coagulation Disorder
- Interventions
- TAK-330, SOC 4F-PCC
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 13
- States / cities
- Arkansas City, Arkansas • Sacramento, California • Englewood, Colorado + 10 more
- Conditions
- Parkinson Disease
- Interventions
- PD Drivers Using AV Technologies On-road
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 35 Years to 85 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Modeling of Recruitment Curves
- Interventions
- Algorithm: Uniform Sampling, Algorithm: hbMEP-adaptive algorithm (version 1), Algorithm: hbMEP-adaptive algorithm (version 2), ML-PEST, MagPro X100 Transcranial Magnetic Stimulation, Digitimer DS8R Transcutaneous Electrical stimulation
- Other · Device
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York